This study is the first to discover the SGLT2 inhibitor can effectively reduce 18F-FDG uptake in skeletal muscle and significantly increase the tumor-to-skeletal muscle ratio in diabetic mice compared with insulin. This evidence concerns the gene SLC5A2 and neoplasm.